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Although cyclophilin A (CyP-A) is a relatively abun-
dant small immunophilin present in the cytoplasm of all
mammalian cells, its general function(s) in the absence
of the immunosuppressant drug cyclosporin A is not
known. In contrast, the high molecular weight hsp90-
binding immunophilins appear to play a role in protein
trafficking in that they have been shown to link glu-
cocorticoid receptor-hsp90 and p53hsp90 complexes to
the dynein motor protein for retrograde movement
along microtubules. These immunophilins link to cyto-
plasmic dynein indirectly through the association of the
immunophilin peptidylprolyl isomerase (PPIase) do-
main with dynamitin, a component of the dynein-asso-
ciated dynactin complex (Galigniana, M. D., Harrell,
J. M., O’Hagen, H. M., Ljungman, M., and Pratt, W. B.
(2004) J. Biol. Chem. 279, 22483–22489). Here, we show
that CyP-A exists in native heterocomplexes containing
cytoplasmic dynein that can be formed in cell-free sys-
tems. Prolyl isomerase activity is not required for form-
ing the dynein complex, but the PPIase domain frag-
ment of FKBP52 blocks complex formation and CyP-A
binds to dynamitin in a PPIase domain-dependent man-
ner. CyP-A heterocomplexes containing tubulin and dy-
nein can be formed in cytosol prepared under microtu-
bule-stabilizing conditions, and CyP-A colocalizes in
mouse fibroblasts with microtubules. Colocalization
with microtubules is disrupted by overexpression of the
PPIase domain fragment. Thus, we conclude that CyP-A
associates in vitro and in vivo with the dynein/dynactin
motor protein complex and we suggest that CyP-A may
perform a general function related to the binding of
cargo for retrograde movement along microtubules.
The cyclophilins (CyPs)1 are members of a large protein
family called immunophilins because of their ability to bind
immunosuppressant drugs (reviewed in Refs. 1 and 2). The
cyclophilins bind the drug cyclosporin A (CsA), and a second
class of immunophilins, the FK506-binding proteins (FKBPs),
binds the immunosuppressant drugs FK506 and rapamycin.
The immunophilins possess peptidylprolyl isomerase (PPIase)
activity, and the immunosuppressant drugs occupy the PPIase
site on the immunophilin, blocking its ability to direct cis-
trans-isomerization of peptidylprolyl bonds in vitro. CyP-A was
isolated as a 17-kDa high affinity binding protein for cyclos-
porin A (3), and it was later shown to be the same as a 17-kDa
protein (4, 5) that was known to have PPIase activity and to
accelerate refolding of urea-denatured protein in vitro (6).
CyP-A was subsequently shown to direct the immunosuppres-
sive effect of CsA (7), and the small FKBP, FKBP12, was shown
to be the target for the immunosuppressive effects of FK506
and rapamycin (8). In both the case of CsA-bound CyP-A and
that of FK506-bound FKBP12, the ultimate target of the drug-
immunophilin complex is the protein phosphatase calcineurin
(for review see Ref. 9). The ultimate target for rapamycin-
bound FKBP12 is a phosphoinositide 3-kinase-related kinase
called FRAP (FKBP-rapamycin-associated protein) (10),
RAFT1 (rapamycin and FKBP12 target 1) (11), or mTOR
(mammalian target of rapamycin) (12). Neither the immuno-
suppressant drugs nor the immunophilins CyP-A and FKBP12
bind alone to the second protein targets for immunosuppres-
sion. Only the drug-immunophilin complexes bind to cal-
cineurin or FRAP/RAFT1/mTOR.
Although most of the work on immunophilins has focused on
the small CyPs and FKBPs, like CyP-A and FKBP12, high
molecular weight immunophilins have been identified that con-
tain domains for additional protein interactions or enzymatic
activity as well as a PPIase domain that binds immunosuppres-
sant drugs (2). Several of these high molecular weight immu-
nophilins were discovered as components of steroid receptor-
hsp90 heterocomplexes. They include CyP-40, FKBP51, and
FKBP52 (reviewed in Ref. 13), and they are not involved in the
immunosuppressant actions of CsA or FK506. These immu-
nophilins possess tetratricopeptide repeat (TPR) domains that
bind to a TPR acceptor site located in the C terminus of the
abundant and ubiquitous protein chaperone hsp90. Two roles
have been proposed for these hsp90-binding immunophilins in
steroid receptor action. Riggs et al. (14) have shown that
FKBP52 selectively potentiates glucocorticoid receptor (GR)-
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dependent reporter gene activation by increasing the hormone-
binding affinity of the receptor. This effect requires the prolyl
isomerase activity of FKBP52 and is blocked by FK506. An-
other line of research has focused on the role of hsp90-binding
immunophilins in targeting the movement of the GR to the
nucleus (reviewed in Ref. 15). The action of these immunophi-
lins in receptor movement is not affected by the presence of
immunosuppressant drugs and thus does not require prolyl
isomerase activity.
In addition to TPR domain immunophilins, GRhsp90 het-
erocomplexes immunoadsorbed from cell lysates contain cyto-
plasmic dynein (16, 17), a molecular motor that processes along
microtubule tracks toward the nucleus (18). In these com-
plexes, the PPIase domain of the immunophilin functions as a
protein-protein-binding domain to link the GRhsp90 unit to
the protein motor (19–21). The immunophilin linkage to cyto-
plasmic dynein is indirect by means of the dynamitin compo-
nent of the dynein-associated dynactin complex (22). The bind-
ing of CyP-40 or FKBP52 to dynein is competed by a purified
PPIase domain fragment of FKBP52 (21), and purified FKBP52
has been shown to bind directly via its PPIase domain to
immunopurified dynamitin (22).
There is a high degree of similarity in PPIase domain struc-
ture among the various cyclophilins (2). The PPIase domain of
bovine CyP-40, for example, shares 61% identity with the se-
quence of human CyP-A ,and with one exception, the active site
residues are identical (2). Thus, we have asked whether CyP-A,
like as its high molecular weight hsp90-binding homolog CyP-
40, binds through its PPIase domain to the dynein/dynactin
complex. Here we show that immunoadsorption of CyP-A from
reticulocyte lysate or L cell cytosol yields coimmunoadsorption
of cytoplasmic dynein. The linkage to dynein is indirect via the
dynamitin component of the dynein-associated dynactin com-
plex, and CyP-A binds to dynamitin in a manner that is com-
peted by a purified PPIase domain fragment of FKBP52. Im-
munoprecipitation of CyP-A from cytosol containing paclitaxel
and GTP to stabilize microtubules yields the coprecipitation of
tubulin and dynein in a PPIase domain-dependent manner,
and Cyp-A colocalizes with microtubules in NIH 3T3 cells. The
observation that CyP-A is associated with the microtubule-
based dynein/dynactin motor protein complex should be useful
in eventually defining the housekeeping function(s) of this sin-
gle domain immunophilin in mammalian cells in the absence of
immunosuppressant drugs.
EXPERIMENTAL PROCEDURES
Materials—Rabbit reticulocyte lysate was from Green Hectares (Or-
egon, WI). Complete Mini protease inhibitor mixture was purchased
from Roche Diagnostics (Mannheim, Germany). Opti-MEM I transfec-
tion medium was from Invitrogen. Trans-Fast transfection reagent was
from Promega (Madison, WI). Enhance chemiluminescence reagents
were from Amersham Biosciences. Glutathione-agarose, protein
A-Sepharose, geldanamycin, hirudin, CsA, paclitaxel, rat monoclonal
IgG against -tubulin, mouse monoclonal IgG against GST, and the
horseradish peroxidase-conjugated donkey anti-mouse and rabbit anti-
rat antibodies were purchased from Sigma. The A-14 rabbit polyclonal
IgG against c-myc oligopeptide was from Santa Cruz Biotechnology
(Santa Cruz, CA). Fluorescent counterantibodies were from Immuno-
Chemicals (West Grove, PA). Horseradish peroxidase-conjugated goat
anti-rabbit IgG and BL21-competent Escherichia coli cells were from
Pierce. The rabbit polyclonal antiserum against CyP-A was prepared in
the Scripps laboratory by immunization with recombinant human
CyP-A protein (23). The mouse monoclonal IgG against the 74-kDa
intermediate chain of mammalian cytoplasmic dynein was purchased
from Chemicon (Temecula, CA).
The pGEX1T plasmid encoding the GST-rabbit FKBP52 Gly32-
Lys138 expression vector that comprises the PPIase core domain I (pro-
vided by Drs. Michel Renoir and Christine Radanyi, UMR8612 CNRS,
Paris, France) and the purification of the PPIase core domain I protein
were described previously (16). The pECFP-N1 plasmid for expressing
cyanine fluorescent protein was provided by Dr. Rainer Benndorf (Uni-
versity of Michigan Medical School, Ann Arbor, MI).
The baculovirus for the FLAG-tagged TPR domain of rat protein
phosphatase 5 (24) was kindly provided by Dr. Michael Chinkers (Uni-
versity of South Alabama, Mobile, AL). The myc-tagged pCMVH50m
construct encoding for p50/dynamitin (25) was a kind gift from Dr.
Richard Vallee (University of Massachusetts Medical School, Worces-
ter, MA). The pGEX-2T plasmid encoding GST-CyP-A was a kind gift
from Dr. Jeremy Luban (Columbia University) (26). All of the incuba-
tion buffers used in these studies were supplemented with protease
inhibitors (1 tablet of Complete Mini Plus 1000 units of hirudin/2 ml of
buffer).
Coimmunoadsorption of Endogenous CyP-A and Dynein—50 l of
reticulocyte lysate were immunoadsorbed to 16 l of protein A-Sepha-
rose with either 5 l of rabbit antiserum against CyP-A or 5 l of mouse
IgG against dynein intermediate chain. After 2 h at 4 °C, the pellets
were washed with TEGM buffer (10 mM TES at pH 7.6, 50 mM NaCl, 4
mM EDTA, 10% v/v glycerol, and 20 mM Na2MoO4). Proteins were
resolved by SDS-polyacrylamide gel electrophoresis, electrotransferred
to an Immobilon P membrane, and Western blotted.
Formation of Complexes with GSH-Agarose-immobilized GST-CyP-
A—80 l of GSH-agarose in 80 l of TEG buffer (TEGM buffer without
molybdate) were incubated at 4 °C for 2 h with 10 l of cytosol from
BL21 E. coli overexpressing either human GST or human GST-CyP-A.
The pellets were washed and reincubated for two additional hours in
TEG buffer supplemented with 0.5 M NaCl and 0.05% Nonidet P-40 and
washed three times with TEG buffer and twice with 10 mM Hepes at pH
7.5. The washed pellets containing immobilized GST-CyP-A (or GST
alone) were incubated for 30 min at 30 °C with 50 l of reticulocyte
lysate supplemented with protease inhibitors, 5 l of an ATP-regener-
ation system (50 mM ATP, 250 mM creatine phosphate, 20 mM magne-
sium acetate, and 100 units/ml creatine phosphokinase), and the indi-
cated peptides in HKD buffer (10 mM Hepes at pH 7.5, 100 mM KCl, and
2 mM dithiothreitol).
Binding of CyP-A to Dynamitin—L929 mouse fibroblasts were grown
in Dulbecco’s modified Eagle’s medium supplemented with 10% bovine
calf serum and antibiotics. When the cells were 50% confluent, the
medium was replaced by Opti-MEM I transfection medium and the
incubation continued for 1 h. The medium was aspirated and replaced
by a transfection mixture (at a 3-l liposome/g DNA ratio) preincu-
bated for 15 min at room temperature in Opti-MEM I, which contained
3 g of the myc-tagged pCMVH50m plasmid encoding for p50/dyna-
mitin. After 1.5 h of transfection, the mixture was replaced by regular
medium. After 36 h, the cells were harvested and ruptured by Dounce
homogenization in HE buffer (10 mM Hepes at pH 7.5, 1 mM EDTA, and
protease inhibitors) and centrifuged at 100,000  g for 30 min. Cell
cytosol (250 l) was rotated for 2 h at 4 °C with 16 l of protein
A-Sepharose and 10 l of anti-myc antibody. The supernatant was
aspirated, and the pellet was stripped of coimmunoadsorbed proteins by
preincubation with buffer supplemented with 0.5 M NaCl and 0.05%
Nonidet P-40. After 2 h, the samples were washed three times with TEG
buffer and twice with HE buffer. The pellets were incubated on ice with
10 l of bacterial lysate overexpressing GST-CyP-A in the presence or
absence of 90 g of purified PPIase domain from FKBP52. The final
volume was adjusted to 50 l with HKD buffer. After 1 h, the pellets
were washed with TEGM buffer and the proteins were resolved by
electrophoresis followed by Western blotting.
Microtubule-stabilized Preparations—L929 fibroblasts were incu-
bated for 15 min with 20 M paclitaxel prior to rupture by Dounce
homogenization in MES buffer (0.1 M Mes, 1 mM EGTA, and 1 mM
MgCl2, pH 6.9) supplemented with 20 M paclitaxel, 100 M GTP, and
protease inhibitors. Prior to adsorption, 0.05% Nonidet P-40 was added
to the cytosol and it was rotated for 30 min at 4 °C and then centrifuged
at 30 p.s.i. for 15 min in an Airfuge. Aliquots (250 l) of cytosol were
incubated at 30 °C for 30 min with 25 l of lysate from nonexpressing
bacteria and 50 l of HKD buffer or 25 l of lysate from bacteria
overexpressing GST-CyP-A and 50 l of HKD buffer or 25 l of lysate
from bacteria overexpressing GST-CyP-A and 325 g of purified PPIase
domain of FKBP52 in HKD buffer. The HKD buffer also contained
protease inhibitors. GST-CyP-A was then immobilized by rotation with
GSH-agarose for 2 h at 4 °C. The pellets were washed with TEGM
buffer, and the proteins were resolved by immunoblotting
Immunoblotting—Immune pellets were resolved on SDS-10% poly-
acrylamide gels and transferred to Immobilon P membranes. The mem-
branes were probed with 0.1% MAB1618 for dynein intermediate chain,
0.1% A-14 for myc-dynamitin, 0.05% rabbit antiserum for CyP-A, and
0.05% mouse IgG for GST.
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Indirect Immunofluorescence—NIH 3T3 cells were grown on 11 
22-mm coverslips coated with fibrinogen in Dulbecco’s modified Eagle’s
medium supplemented with 10% bovine calf serum and antibiotics. The
coverslips were rinsed with phosphate-saline solution and fixed for 4 h
in a freshly prepared 4% p-formaldehyde solution in phosphate-saline
buffer. Cells were permeabilized by immersing the coverslips in acetone
at 20 °C for 15 min. After washing the coverslips with phosphate-
saline buffer, they were preincubated for 1 h at room temperature in
HISS (high ionic strength solution) buffer (20 mM Tris at pH 8.0, 0.63 M
NaCl, 0.1% Tween 20, and 3.5% bovine serum albumin) supplemented
with 1% horse serum.
The cells were washed in HISS buffer and immunostained by invert-
ing the coverslips on a 50-l solution of HISS buffer containing 1 l of
rat anti--tubulin and 0.2 l of rabbit anti-CyP-A serum. After 2 h at
room temperature in a humid chamber, the cells were washed in HISS
buffer for 1 h at room temperature and then incubated with a 1/100
dilution of the corresponding counter-antibodies (rhodamine-conju-
gated donkey anti-rabbit IgG and fluorescein isothiocyanate-conjugated
donkey anti-rat IgG). The coverslips were mounted on microscope slides
using a drop of Antifade mounting medium (Molecular Probes, Leiden,
The Netherlands), and the cells were observed with an Olympus Fluo-
view-500 confocal microscope.
RESULTS
CyP-A Is Recovered in Native Heterocomplex with Dy-
nein—To determine whether CyP-A exists in native heterocom-
plexes with dynein, reticulocyte lysate was immunoadsorbed
with antibodies directed against the immunophilin or against
the intermediate chain of dynein and proteins associated with
the washed immune pellets were detected by immunoblotting.
As shown in Fig. 1A, immunoadsorption of dynein yielded
coadsorption of CyP-A (lane 3) and immunoadsorption of CyP-A
yielded coadsorption of dynein (lane 5), consistent with the
notion that CyP-A exists in native heterocomplexes with cyto-
plasmic dynein. In Fig. 1, lanes 6–9, the entire lanes for each
immunopellet were blotted with each antibody to demonstrate
the specificity of the interaction. To show that the complex does
not involve only small amounts of either protein, a large
amount of CyP-A was immunoadsorbed from reticulocyte ly-
sate and the resulting immunodepletion of dynein was as-
sessed. As shown in Fig. 1B, increasing immunoadsorption of
CyP-A was accompanied by increasing coadsorption of dynein
(lanes 3 and 4). At the higher amount of antibody, most of the
CyP-A and a substantial amount of the dynein were adsorbed
from reticulocyte lysate (cf. lane 7 with lane 5). By scanning the
lanes with a PhosphorImager and subtracting an adjacent
background value, arbitrary units for each protein remaining
in nonimmune (lane 5) and the highest immune (lane 7) super-
natant were determined. A depletion of 75% CyP-A yielded 59%
codepletion of dynein, indicating that a majority of each protein
is in a heterocomplex containing the other protein.
To show that the binding is not a weak and possibly nonspe-
cific interaction, reticulocyte lysate was immunoadsorbed with
anti-CyP-A and the immune pellets were washed under in-
creasingly harsh conditions. As shown in Fig. 1C, the complex
of CyP-A with dynein persisted upon washing with TEG buffer
plus 100 mM NaCl (cf. lanes 2 and 3) and washing with TEG
plus NaCl and 0.1% Nonidet P-40 (lane 3). Washing under very
harsh detergent conditions (NaCl, Nonidet P-40, 0.5% deoxy-
cholate, and 1% sodium dodecyl sulfate) dissociates the CyP-A
antibody from the protein A-Sepharose pellet such that most of
the CyP-A and dynein are lost. Nevertheless, some complex of
CyP-A and dynein can be seen under these very harsh condi-
tions of washing (lane 5).
We have previously used reticulocyte lysate to achieve cell-
free assembly of GRhsp90 complexes that contain hsp90-bind-
ing immunophilins and dynein (16). In the experiment of Fig. 2,
GST-CyP-A was immobilized onto glutathione beads and the
beads were incubated with reticulocyte lysate under the same
GR heterocomplex assembly conditions. Glutathione beads
bound with GST alone did not contain dynein after incubation
with reticulocyte lysate (lane 2), but GST-CyP-A-bound beads
contained dynein (lane 5).
CyP-A PPIase Domain Is Required for Complex with Dy-
nein—The formation of heterocomplexes containing the hsp90-
binding immunophilins and dynein requires the PPIase do-
main of the immunophilin and can be blocked by competition
with the PPIase domain fragment of FKBP52 (16, 19–21). In
the experiment of Fig. 3, GST-CyP-A-bound beads were incu-
bated with reticulocyte lysate in the presence of lysate from
bacteria expressing the FKBP52 PPIase domain fragment and
the beads were then washed and assayed for bound proteins.
The presence of the PPIase domain fragment prevented CyP-A
association with dynein (cf. lanes 2 and 4), whereas the pres-
ence of a TPR domain fragment did not affect dynein binding
(lane 5). We have shown previously that the TPR domain frag-
ment inhibits the binding of TPR domain immunophilins to
hsp90 but does not affect their binding to dynein (16). Impor-
tantly, CsA does not affect the formation of a CyP-A complex
with dynein (lane 6), suggesting that prolyl isomerase activity
is not required.
CyP-A Interaction with Dynamitin—Recently, we have dem-
onstrated that purified FKBP52 binds directly to purified myc-
dynamitin, a 50-kDa component of the dynein-associated dyn-
actin complex (22). In Fig. 4, anti-myc antibody was used to
immunoadsorb cytosol from cells overexpressing myc-dyna-
mitin and the salt-stripped immune pellet was incubated with
lysate from bacteria expressing GST-CyP-A. The GST-CyP-A
bound to myc-dynamitin (condition 2), and the binding was
blocked by the PPIase fragment of FKBP52 (condition 3). Thus,
similar to the hsp90-binding immunophilins, CyP-A appears to
associate with dynein indirectly by binding to dynamitin.
Tubulin Is Present in the CyP-A Heterocomplexes—We have
recently shown that GR heterocomplexes immunoadsorbed
from L cell cytosol prepared with a microtubule-stabilizing
buffer contain tubulin as well as dynein.2 In the experiment of
Fig. 5, L cells were treated briefly with paclitaxel and then
ruptured in buffer containing both paclitaxel and GTP to sta-
bilize microtubules. Cytosol was also prepared without the
microtubule-stabilizing conditions. Lysate from bacteria ex-
pressing GST-CyP-A was added to each cytosol preparation,
the mixture was incubated, and the GST-CyP-A was adsorbed
to glutathione beads. As shown in Fig. 5, condition 2, dynein is
present in GST-CyP-A pellets prepared under either condition
but tubulin is present only when GST-CyP-A is adsorbed from
cytosol prepared under microtubule-stabilizing conditions. If
the PPIase domain fragment is present to compete for CyP-A
binding to dynamitin, neither dynein nor tubulin is present in
the GST-CyP-A pellet (condition 3). This finding supports a
model in which CyP-A is linked to microtubules via its associ-
ation with the dynein/dynactin complex.
CyP-A Is Localized to Microtubules in Vivo—In Fig. 6, 3T3
mouse fibroblasts were cotransfected with plasmids encoding
for the PPIase domain fragment of FKBP52 and cyanine fluo-
rescent protein. After 36 h, the cells were fixed and immuno-
stained for tubulin (Fig. 6A, green) and CyP-A (Fig. 6B, red). In
the untransfected cells, CyP-A is seen to colocalize with tubulin
(see merge in Fig. 6C). The blue image in Fig. 6D shows a
cotransfected cell in the middle of the field. The expression of
the PPIase domain fragment did not affect the fibrillar pattern
of the microtubules (Fig. 6A), but it disrupted the fibrillar
distribution of CyP-A (Fig. 6B). This is consistent with the
2 J. M. Harrell, M. D. Galigniana, P. J. M. Murphy, Y. Morishima,
and W. B. Pratt, manuscript in preparation.
Cyclophilin-A and Dynein55756
FIG. 1. Coimmunoadsorption of CyP-A and dynein. A, native complexes. Aliquots (50 l) of reticulocyte lysate were immunoadsorbed to
protein A-Sepharose with antibody against CyP-A or dynein intermediate chain (DIC), the immune pellets were washed, and pellet-bound proteins
were resolved by SDS-polyacrylamide gel electrophoresis and immunoblotting. Lane 1, 4 l of reticulocyte lysate; lane 2, nonimmune mouse IgG
pellet; lane 3, anti-DIC immunopellet; lane 4, nonimmune rabbit serum pellet; lane 5, anti-CyP-A immunopellet. These lanes were cut in half, and
the top was immunoblotted with anti-DIC and the bottom was immunoblotted with anti-CyP-A. Lanes 6 and 7, immunoadsorbed with anti-DIC
and immunoblotted with anti-DIC (lane 6) or anti-CyP-A (lane 7). Lanes 8 and 9, immunoadsorbed with anti-CyP-A and immunoblotted with
anti-DIC (lane 8) or anti-CyP-A (lane 9). For lanes 6–9, the full lanes that are immunoblotted show the specificity of the antibodies. HC, antibody
heavy chain; LC, light chain. B, CyP-A is in complex with a substantial amount of dynein. Aliquots (25 l) of reticulocyte lysate were
immunoadsorbed with 4 l of nonimmune antiserum or 2.5 or 5 l of anti-CyP-A. The immune pellets and supernatants were resolved by
SDS-polyacrylamide gel electrophoresis and immunoblotting with anti-DIC (top) or anti-CyP-A (bottom). Lane 1, aliquot of reticulocyte lysate; lanes
2–4, immune pellets from nonimmune antiserum (lane 2), 2.5 l of anti-CyP-A (lane 3), and 5 l of anti-CyP-A (lane 4); lanes 5–7, supernatants
of the immunoadsorption with nonimmune antiserum (lane 5), 2.5 l of anti-CyP-A (lane 6), and 5 l of anti-CyP-A (lane 7). The exposure time for
the immunoblot was selected after various exposure times to avoid saturation such that the signals fall in the linear range of the film, which was
scanned with a PhosphorImager to yield the percentage of each protein that was immunoadsorbed as presented under “Results.” C, the CyP-A
complex with dynein withstands washing under stringent conditions. Aliquots (25 l) of reticulocyte lysate were immunoadsorbed to protein
A-Sepharose with antibody against CyP-A, and the immune pellets were washed twice with TEG buffer plus the indicated additions and once
with HE buffer. Lane 1, nonimmune pellet washed with TEG alone; lanes 2–5, immune pellets washed with TEG alone (lane 2), TEG plus 100 mM
NaCl (lane 3), TEG plus NaCl and 0.1% Nonidet P-40 (lane 4), and TEG plus NaCl, Nonidet P-40, 0.5% deoxycholate, and 1% sodium dodecyl sulfate
(lane 5).
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PPIase domain fragment competing for the localization of
CyP-A to microtubules.
DISCUSSION
Here, we have shown that the single domain immunophilin,
CyP-A, behaves like the hsp90-binding TPR domain immu-
nophilins in binding to the cytoplasmic dynein motor protein
complex (Fig. 1). The PPIase domain fragment of FKBP52
competes for dynein binding; however, inasmuch as binding
occurs in the presence or absence CsA (Fig. 3), the isomerase
activity of CyP-A is not required. Thus, the binding of immu-
nophilin PPIase domains to the motor protein complex is very
different from the binding of CyP-A or FKBP12 to calcineurin
where only the CsA- or FK506-bound immunophilin is a cal-
cineurin binding partner. Again, like the hsp90-binding immu-
nophilins, CyP-A appears to bind to dynein indirectly through
an interaction of its PPIase domain with the dynamitin com-
ponent of the dynein-associated dynactin complex (Fig. 4).
Cytoplasmic dynein motors process along microtubules
tracks, and we show that CyP-A heterocomplexes containing
tubulin and dynein can be formed in cytosol under microtu-
bule-stabilizing conditions (Fig. 5). Importantly, we show
that CyP-A colocalizes with microtubules in 3T3 mouse fibro-
blasts and that binding to microtubules in vivo is disrupted
by overexpression of the PPIase domain fragment of FKBP52
(Fig. 6). Taken together, the in vitro and in vivo observations
support a model in which CyP-A is associated with the ret-
rograde movement system as a CyP-A-dynamitin-dynein-mi-
crotubule complex.
CyP-A is present as a relatively abundant protein in the
cytoplasm of all mammalian cells (2). Thus, it must perform
some general housekeeping function(s) important for cellular
homeostasis. To date, the studies of CyP-A have largely focused
on its structure and its immunosuppressive action through the
association of the CyP-ACsA complex with calcineurin (1, 2).
Occasional reports have noted the CyP-A association with spe-
FIG. 2. Cell-free formation of CyP-A complexes containing dy-
nein. Glutathione beads were mixed with GST or lysate from nonex-
pressing bacteria or lysate from bacteria expressing GST-CyP-A. The
beads were then incubated with 0.5 M NaCl, washed, and incubated for
30 min at 30 °C with 50 l of reticulocyte lysate or HKD buffer. The
beads were then washed, and proteins were resolved by electrophoresis
and immunoblotting. Lane 1, 6 l of reticulocyte lysate; lane 2, GST-
bound beads incubated with reticulocyte lysate; lane 3, beads bound
with nonexpressing bacterial lysate incubated with reticulocyte lysate;
lane 4, GST-CyP-A-bound beads incubated with HKD buffer; lane 5,
GST-CyP-A-bound beads incubated with reticulocyte lysate; lane 6, 1 l
of lysate from bacteria expressing GST-CyP-A.
FIG. 3. Formation of a complex containing CyP-A and dynein
is inhibited by the PPIase domain fragment of FKBP52. GST-
bound beads (lane 1) or GST-CyP-A-bound beads (lanes 2–7) were
incubated with 50 l of reticulocyte lysate and HKD buffer (lanes 1 and
2), 10 l of nonexpressing bacterial lysate (lane 3), 10 l of lysate from
bacteria expressing the PPIase domain fragment of FKBP52 (lane 4), 50
g of purified TPR domain of PP5 (lane 5), or 1 M CsA (lane 6). The
final volume was adjusted to 77 l with HKD buffer. After the incuba-
tion, the beads were washed and proteins were resolved by electro-
phoresis and immunoblotting.
FIG. 4. CyP-A binds to purified dynamitin. Aliquots (250 l) of
cytosol from L cells overexpressing myc-dynamitin (myc-Dyt) were im-
munoadsorbed with nonimmune serum (NI) or with anti-myc serum (I).
The immune pellets were incubated with 0.5 M NaCl, washed, and
incubated for 1 h at 0 °C with 10 l of lysate from nonexpressing
bacteria (condition 1), 10 l of lysate from bacteria expressing GST-
CyP-A (condition 2), or 10 l of lysate from bacteria expressing GST-
CyP-A plus 90 g of purified PPIase domain from FKBP52 (condition 3).
The immune pellets were washed, and proteins were resolved by elec-
trophoresis and immunoblotting.
FIG. 5. CyP-A forms a complex containing tubulin in a PPIase
domain-dependent manner. L cells were incubated with vehicle ()
or 20 M paclitaxel () for 15 min prior to Dounce homogenization in
tubulin-stabilizing buffer containing () 20 M paclitaxel and 100 M
GTP or not (). Aliquots (250 l) of cytosol were incubated for 30 min
at 30 °C with lysate from nonexpressing bacteria (condition 1) or with
lysate from bacteria overexpressing GST-CyP-A plus HKD buffer (con-
dition 2) or with lysate from bacteria overexpressing GST-CyP-A plus
the purified PPIase domain of FKBP52 (condition 3). GST-CyP-A was
then immobilized by rotation with GSH-agarose, the pellets were
washed, and the proteins were resolved by electrophoresis and
immunoblotting.
FIG. 6. Cytoplasmic CyP-A colocalizes with microtubules. NIH
3T3 fibroblasts were cotransfected with 1 g of pECFP (cyanine fluo-
rescent protein) and 8 g of pSG5PL-FKBP52 core domain I (PPIase
domain fragment of FKBP52). After 36 h, the cells were fixed and
immunostained for tubulin (A) and CyP-A (B). Panel C is a merge of
images A and B, and panel D identifies the transfected cell by blue
fluorescence. Bar C is 10 m.
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cific proteins, such as the YY1 suppressor of gene transcription
(27) and human immunodeficiency virus, type 1 Pr55gag
polyprotein precursor (26, 28). However, the associations re-
ported have not led to a general model for CyP-A function in
mammalian cells in the absence of CsA. The association of
CyP-A with the dynein/dynactin motor protein complex could
reveal a general housekeeping function. Dynein is thought to
link to its cargo indirectly through dynactin, but it is not known
how cargo is recognized (29). We summarized in the Introduc-
tion how the TPR domain immunophilins target two hsp90-
regulated proteins, the GR and p53, to the dynein/dynactin
complex for their retrograde movement to the nucleus (15).
CyP-A could participate in such cargo recognition either di-
rectly or indirectly as part of a protein complex. Interestingly,
there are several lines of evidence suggesting that HIV uses
dynein and the microtubule network to transport its genome to
the nucleus. Because HIV requires CyP-A to efficiently repli-
cate in human cells (30, 31), one can envision that CyP-A acts
as connector between HIV and the microtubule network in
order to facilitate a secured convey of the viral genome to the
nucleus.
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